PDE4B and idiopathic pulmonary fibrosis: The FIBRONEERTM-ON OLE will allow the safety, tolerability, and efficacy of the preferential PDE4B inhibitor nerandomilast to be investigated in patients with IPF and PPF over a longer duration compared with the parent trials.